Holen Sie sich die Stockscreener-App
103.40
3.37%
-3.61
Schlusskurs vom Vortag:
$107.01
Offen:
$106.25
24-Stunden-Volumen:
509.46K
Relative Volume:
0.66
Marktkapitalisierung:
$8.51B
Einnahmen:
$51.48M
Nettoeinkommen (Verlust:
$-315.00M
KGV:
-28.96
EPS:
-3.5708
Netto-Cashflow:
$-244.00M
1W Leistung:
-6.48%
1M Leistung:
-9.83%
6M Leistung:
+42.25%
1J Leistung:
+136.34%
1-Tages-Spanne:
$102.13
$106.72
1-Wochen-Bereich:
$102.13
$113.00
52-Wochen-Spanne:
$36.65
$130.05
Kymera Therapeutics Inc Stock (KYMR) Company Profile
Firmenname
Kymera Therapeutics Inc
Sektor
Branche
Telefon
857-285-5314
Adresse
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Compare KYMR vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
103.40 | 9.05B | 51.48M | -315.00M | -244.00M | -3.5708 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-05-06 | Eingeleitet | Canaccord Genuity | Buy |
| 2026-03-16 | Fortgesetzt | Jefferies | Buy |
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2026-01-06 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-11-03 | Fortgesetzt | Guggenheim | Buy |
| 2025-10-24 | Bestätigt | B. Riley Securities | Buy |
| 2025-10-21 | Eingeleitet | Mizuho | Outperform |
| 2025-09-18 | Bestätigt | H.C. Wainwright | Buy |
| 2025-09-17 | Eingeleitet | Barclays | Overweight |
| 2025-09-16 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-07-30 | Fortgesetzt | B. Riley Securities | Buy |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-06-03 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2025-06-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-06-02 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-05-20 | Fortgesetzt | Stifel | Buy |
| 2025-03-13 | Eingeleitet | Citigroup | Buy |
| 2024-12-10 | Eingeleitet | BTIG Research | Buy |
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2024-12-02 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-08-26 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2024-04-22 | Eingeleitet | Oppenheimer | Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-01-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-06-30 | Eingeleitet | Truist | Buy |
| 2023-05-05 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-12-06 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-11-08 | Eingeleitet | Raymond James | Mkt Perform |
| 2022-08-15 | Eingeleitet | Jefferies | Buy |
| 2022-08-03 | Eingeleitet | Goldman | Buy |
| 2022-07-20 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | JP Morgan | Neutral |
| 2022-02-10 | Eingeleitet | Wells Fargo | Overweight |
| 2021-09-30 | Eingeleitet | B. Riley Securities | Neutral |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-09-10 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-14 | Eingeleitet | Berenberg | Buy |
| 2020-12-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-09-15 | Eingeleitet | BofA Securities | Neutral |
| 2020-09-15 | Eingeleitet | Cowen | Outperform |
| 2020-09-15 | Eingeleitet | Guggenheim | Buy |
| 2020-09-15 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Kymera Therapeutics Inc Aktie (KYMR) Neueste Nachrichten
KYMR Maintained by Guggenheim -- Price Target Raised to $135 - GuruFocus
Guggenheim raises Kymera Therapeutics price target on IRF5 program By Investing.com - Investing.com Canada
KYMR Looks 356.6% Overvalued on GF Value™ - GuruFocus
Form 4 Kymera Therapeutics Inc For: 27 July By Investing.com - Investing.com South Africa
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer - Investing News Network
Kymera Therapeutics names Terence Rooney as chief medical officer - Investing.com
Kymera Therapeutics names Terence Rooney as new Chief Medical Officer to lead clinical development. - Pluang
Kymera Therapeutics (NASDAQ: KYMR) names Terence Rooney as new CMO - Stock Titan
Johnson & Johnson Immunology Leader Joins Kymera as Chief Medical Officer - Stock Titan
Kymera Therapeutics officers probed for possible self-dealing, shareholders urged to act. - Pluang
Kymera Therapeutics Inc (KYMR) Cash Flow - TradingKey
Kymera Therapeutics Inc (KYMR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Kymera Therapeutics Inc (KYMR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
KYMR|Kymera Therapeutics Inc|Price:110.570|Chg%:+0.190 - TradingKey
KYMR|Kymera Therapeutics Inc|Price:110.320|Chg%:-0.250 - TradingKey
Is Kymera Therapeutics Poised for a Breakthrough With KT-621? - Yahoo Finance
Kymera Therapeutics Inc (KYMR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
💪💪💪💪💪💪💪💪💪💪💪 - Moomoo
Kymera Therapeutics stock slips to $111.06 amid selling pressure and volatile trading - Traders Union
Kymera Therapeutics, Inc. (KYMR) Stock Analysis: A Promising Biotech with a 12.68% Upside - DirectorsTalk Interviews
(KYMR) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Law firm probes Kymera Therapeutics' officers f... - Pluang
KYMR Maintained by Mizuho -- Price Target Raised to $140 - GuruFocus
Piper Sandler Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $140 - Moomoo
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR) - PR Newswire
Kymera Therapeutics Price Target Raised to $140.00/Share From $120.00 by Mizuho - Moomoo
Mizuho Securities Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Announces Target Price $140 - Moomoo
Kymera Therapeutics (KYMR) AGM 2024 Summary - Quartr
Kymera Therapeutics (KYMR) Jefferies London Healthcare Conference 2025 Summary - Quartr
Kymera Therapeutics (KYMR) 44th Annual J.P. Morgan Healthcare Conference Summary - Quartr
Form 144 Kymera Therapeutics For: 13 July By Investing.com - Investing.com Nigeria
RBC Capital Markets has adjusted its investment rating for Kymera Therapeutics Inc., downgrading it from "outperform" to "sector perform." - Bitget
Kymera Therapeutics Shares Fall After RBC Downgrade - Moomoo
RBC Downgrades Kymera Therapeutics to Sector Perform From Outperform, Lifts Price Target to $115 From $106, Keeps Speculative Risk - marketscreener.com
Kymera's CEO Sold $6 Million in Stock After a 170% Run - The Globe and Mail
Kymera's CEO Sold $6 Million in Stock After a 170% Run - The Motley Fool
BTIG maintains Kymera Therapeutics (KYMR) buy recommendation - MSN
Strength seen in Kymera Therapeutics (KYMR): Can its 16.6% jump turn into more strength? - MSN
Is Kymera (KYMR) the Best Performing American Stock in June 2026? - Insider Monkey
Kymera jumps 17% on early enrollment completion in skin disease study - MSN
Kymera's High-Flying Stock Meets Insider Selling - Kavout | AI
Hedge Fund and Insider Trading News: Bill Ackman, Ken Griffin, Warren Buffett, Ray Dalio, Scion Asset Management, Brevan Howard, Kymera Therapeutics Inc (KYMR), Sony Group Corp (SONY), and More - Insider Monkey
Kymera Therapeutics Insider Sold Shares Worth $5,950,000, According to a Recent SEC Filing - marketscreener.com
Kymera Therapeutics (KYMR) Citi's Biopharma Back to School Conference Summary - Quartr
Kymera Therapeutics(KYMR.US) Officer Sells US$5.95 Million in Common Stock - Moomoo
Form 4 Kymera Therapeutics Inc For: 7 July By Investing.com - Investing.com Canada
Kymera Therapeutics CEO Mainolfi sells $5.95m in stock By Investing.com - Investing.com India
Kymera Therapeutics CEO Mainolfi sells $5.95m in stock - Investing.com
Form 144 Kymera Therapeutics For: 7 July By Investing.com - Investing.com Nigeria
Kymera Therapeutics, Inc. Announces Appointment of Elizabeth Laws as Senior Vice President - marketscreener.com
Kymera hires ex-Sanofi executive to lead KT-621 development - Investing.com
Finanzdaten der Kymera Therapeutics Inc-Aktie (KYMR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Kymera Therapeutics Inc-Aktie (KYMR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Mainolfi Nello | Chief Executive Officer |
Jul 07 '26 |
Sale |
119.00 |
50,000 |
5,950,000 |
666,568 |
2.44%
0.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):